"10.1371_journal.pone.0055091","plos one","2013-02-06T00:00:00Z","Ping He; Xin Cheng; Matthias Staufenbiel; Rena Li; Yong Shen","Center for Advanced Therapeutic Strategies of Brain Disorders, Roskamp Institute, Sarasota, Florida, United States of America; Department of Neurology and Institute of Neurology, Huashan Hospital, Fudan University, Shanghai, China; Novartis Pharm Ltd., Nervous System Research, Basel, Switzerland; Center for Hormone Advanced Science and Education, Roskamp Institute, Sarasota, Florida, United States of America","Examined and analyzed the data: PH YS. Conceived and designed the experiments: YS RL. Performed the experiments: PH XC. Contributed reagents/materials/analysis tools: MS. Wrote the paper: PH YS RL.","Matthias Staufenbiel is employed by Novartis Pharm Ltd. APP23 transgenic (20 males and 20 females in each age group) and non-transgenic wild type (20 males and 20 females in each age group) genotypes in our experiment are on the C57BL/6 background, which were provided by Novartis Institute for Biomedical Research. There are no patents, products in development or marketed products to declare. This does not alter the authorsâ€™ adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.","2013","02","Ping He","PH",5,TRUE,2,2,2,3,TRUE,TRUE,FALSE,0,NA,FALSE
